VATS Major Lung Resection for Chinese Early-stage Non-small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Surgery may be the best treatment choice for early stage non-small cell lung cancer. And VATS major lung resection have been preferred as a standard radical procedure for early stage non-small cell lung cancer (NSCLC).This study aim to investigate the outcome of VATS major lung resection for lung cancer as a real-world study in china.

Detailed Description
-----------------
Surgery may be the best treatment choice for early stage non-small cell lung cancer. And VATS major lung resection have been preferred as a standard radical procedure for early stage non-small cell lung cancer (NSCLC).This study aim to investigate the outcome of VATS major lung resection for lung cancer as a real-world study in china.This is a multicenter, prospective study, aimed To evaluate the short-term and long- term outcome of VATS major lung resection for early stage lung cancer. Patients will be followed up every 3 months for 3 years.

Official Title
-----------------
VATS Major Lung Resection for Chinese Early-stage Non-small Cell Lung cancer-a Registry Study

Conditions
-----------------
Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Procedure: Thoracoscopy/VATS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preoperative criteria: i) non-small cell lung cancer is suspected, ii) clinical stage I/II (3) Intraoperative criteria: i) Histologically confirmed NSCLC, ii) resected by VATS or converted open lobectomy,sleeve lobectomy or pneumonectomy and nodal dissection/sampling. (4) No prior ipsilateral thoracotomy (prior diagnostic thoracoscopy is allowed). (5) No prior chemotherapy or radiation therapy for any malignant diseases. (6) Expected postoperative FEV1.0>=800 mL and PaO2>=65 torr. (7) Performance status of 0 or 1. (8) Sufficient organ functions. (9) Written informed consent. Exclusion Criteria: Active bacterial or fungous infection. Simultaneous or metachronous (within the past 5 years) double cancers. Women during pregnancy or breast-feeding. Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema. Psychosis. Systemic steroids medication. Uncontrollable diabetes mellitus. Uncontrollable hypertension. History of severe heart disease, heart failure, myocardial infarction within the past 6 months or attack of angina pectoris within the past 6 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| major lung resection<br>Patients undergo major lung resection by thoracoscopy/VATS. | Procedure: Thoracoscopy/VATS<br>* Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.<br>* Other names: Minimal invasive surgery;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| morbidity and mortility rate | perioperative complications and death rates of the group | 3 moths | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease-free survival | To evaluate Disease Free Survival (DFS) of the group. | 3y | 
| Rate of loco-regional and systemic recurrence | To evaluate the rate of loco-regional and systemic recurrence of the group. | 3y | 
| Pulmonary function | to evaluate the pulmonary function as measured by expiratory flow rate of the group 6 months postoperatively. | 6 months after surgery | 
| Postoperative hospital stay. | to evaluate the postoperative hospital stay of the group. | 3 months postoperatively | 
| Postoperative drainage duration | to evaluate the postoperative drainage duration of the group. | 3 months postoperatively | 
| overall survival | to evaluate the overall survival rate of the group. | 3 months postoperatively | 
| converted rate | the rate of converted thoracotomy | 3 months |